167 related articles for article (PubMed ID: 11021735)
1. Effect of tamoxifen pretreatment on the pharmacokinetics, metabolism and cardiotoxicity of doxorubicin in female rats.
Vaidyanathan S; Boroujerdi M
Cancer Chemother Pharmacol; 2000; 46(3):185-92. PubMed ID: 11021735
[TBL] [Abstract][Full Text] [Related]
2. Inhibition of aldo-keto reductases by phenobarbital alters metabolism, pharmacokinetics and toxicity of doxorubicin in rats.
Behnia K; Boroujerdi M
J Pharm Pharmacol; 1999 Nov; 51(11):1275-82. PubMed ID: 10632085
[TBL] [Abstract][Full Text] [Related]
3. Investigation of the influence of modulation of P-glycoprotein by a multiple dosing regimen of tamoxifen on the pharmacokinetics and toxicodynamics of doxorubicin.
Darvari R; Boroujerdi M
Cancer Chemother Pharmacol; 2005 Nov; 56(5):497-509. PubMed ID: 15937726
[TBL] [Abstract][Full Text] [Related]
4. Interaction of dexrazoxane with red blood cells and hemoglobin alters pharmacokinetics of doxorubicin.
Vaidyanathan S; Boroujerdi M
Cancer Chemother Pharmacol; 2000; 46(2):93-100. PubMed ID: 10972478
[TBL] [Abstract][Full Text] [Related]
5. New aspects in probucol cardioprotection against doxorubicin-induced cardiotoxicity.
El-Demerdash E; Ali AA; Sayed-Ahmed MM; Osman AM
Cancer Chemother Pharmacol; 2003 Nov; 52(5):411-6. PubMed ID: 12879278
[TBL] [Abstract][Full Text] [Related]
6. Contradistinction between doxorubicin and epirubicin: in-vivo metabolism, pharmacokinetics and toxicodynamics after single- and multiple-dosing in rats.
Ramanathan-Girish S; Boroujerdi M
J Pharm Pharmacol; 2001 Jul; 53(7):987-97. PubMed ID: 11480551
[TBL] [Abstract][Full Text] [Related]
7. Effect of multidrug resistance modulators on the hepatobiliary disposition of doxorubicin in the isolated perfused rat liver.
Booth CL; Brouwer KR; Brouwer KL
Cancer Res; 1998 Aug; 58(16):3641-8. PubMed ID: 9721873
[TBL] [Abstract][Full Text] [Related]
8. Pharmacology of N-benzyladriamycin-14-valerate in the rat.
Sweatman TW; Seshadri R; Israel M
Cancer Chemother Pharmacol; 1999; 43(5):419-26. PubMed ID: 10100599
[TBL] [Abstract][Full Text] [Related]
9. A short-time model to study relevant indices of cardiotoxicity of doxorubicin in the rat.
Hole LD; Larsen TH; Fossan KO; Limé F; Schjøtt J
Toxicol Mech Methods; 2013 Jul; 23(6):412-8. PubMed ID: 23379389
[TBL] [Abstract][Full Text] [Related]
10. Effects of 17α-ethynylestradiol-induced cholestasis on the pharmacokinetics of doxorubicin in rats: reduced biliary excretion and hepatic metabolism of doxorubicin.
Choi YH; Lee YK; Lee MG
Xenobiotica; 2013 Oct; 43(10):901-7. PubMed ID: 23574017
[TBL] [Abstract][Full Text] [Related]
11. Investigation of the enterohepatic recirculation of Adriamycin and its metabolites by a linked-rat model.
Behnia K; Boroujerdi M
Cancer Chemother Pharmacol; 1998; 41(5):370-6. PubMed ID: 9523732
[TBL] [Abstract][Full Text] [Related]
12. NTP Toxicology and Carcinogenesis Studies of Coumarin (CAS No. 91-64-5) in F344/N Rats and B6C3F1 Mice (Gavage Studies).
National Toxicology Program
Natl Toxicol Program Tech Rep Ser; 1993 Sep; 422():1-340. PubMed ID: 12616289
[TBL] [Abstract][Full Text] [Related]
13. Amelioration of doxorubicin-induced cardiac and renal toxicity by pirfenidone in rats.
Giri SN; Al-Bayati MA; Du X; Schelegle E; Mohr FC; Margolin SB
Cancer Chemother Pharmacol; 2004 Feb; 53(2):141-50. PubMed ID: 14564477
[TBL] [Abstract][Full Text] [Related]
14. Increased accumulation of doxorubicin and doxorubicinol in cardiac tissue of mice lacking mdr1a P-glycoprotein.
van Asperen J; van Tellingen O; Tijssen F; Schinkel AH; Beijnen JH
Br J Cancer; 1999 Jan; 79(1):108-13. PubMed ID: 10408701
[TBL] [Abstract][Full Text] [Related]
15. Procyanidins produce significant attenuation of doxorubicin-induced cardiotoxicity via suppression of oxidative stress.
Li W; Xu B; Xu J; Wu XL
Basic Clin Pharmacol Toxicol; 2009 Mar; 104(3):192-7. PubMed ID: 19143757
[TBL] [Abstract][Full Text] [Related]
16. The effect of tamoxifen on the pharmacokinetics of letrozole in female rats.
Tao X; Brodie AM; Nnane IP
Biopharm Drug Dispos; 2006 Oct; 27(7):335-44. PubMed ID: 16912967
[TBL] [Abstract][Full Text] [Related]
17. Mechanism of protection of moderately diet restricted rats against doxorubicin-induced acute cardiotoxicity.
Mitra MS; Donthamsetty S; White B; Latendresse JR; Mehendale HM
Toxicol Appl Pharmacol; 2007 Nov; 225(1):90-101. PubMed ID: 17904602
[TBL] [Abstract][Full Text] [Related]
18. Biocompatible microemulsion modifies the pharmacokinetic profile and cardiotoxicity of doxorubicin.
Assumpção JU; Campos ML; Ferraz Nogueira Filho MA; Pestana KC; Baldan HM; Formariz Pilon TP; de Oliveira AG; Peccinini RG
J Pharm Sci; 2013 Jan; 102(1):289-96. PubMed ID: 23150468
[TBL] [Abstract][Full Text] [Related]
19. The role of biotransformation in anthracycline-induced cardiotoxicity in mice.
de Jong J; Schoofs PR; Snabilié AM; Bast A; van der Vijgh WJ
J Pharmacol Exp Ther; 1993 Sep; 266(3):1312-20. PubMed ID: 8371139
[TBL] [Abstract][Full Text] [Related]
20. Concentration dependency of modulatory effect of amlodipine on P-glycoprotein efflux activity of doxorubicin--a comparison with tamoxifen.
Darvari R; Boroujerdi M
J Pharm Pharmacol; 2004 Aug; 56(8):985-91. PubMed ID: 15285842
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
